Dissemin is shutting down on January 1st, 2025

Published in

MDPI, Pharmaceuticals, 6(16), p. 822, 2023

DOI: 10.3390/ph16060822

Links

Tools

Export citation

Search in Google Scholar

Adenylosuccinic Acid: An Orphan Drug with Untapped Potential

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Adenylosuccinic acid (ASA) is an orphan drug that was once investigated for clinical application in Duchenne muscular dystrophy (DMD). Endogenous ASA participates in purine recycling and energy homeostasis but might also be crucial for averting inflammation and other forms of cellular stress during intense energy demand and maintaining tissue biomass and glucose disposal. This article documents the known biological functions of ASA and explores its potential application for the treatment of neuromuscular and other chronic diseases.